These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1149 related articles for article (PubMed ID: 22944464)

  • 21. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
    Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
    Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thyroid-stimulating hormone-stimulated fused positron emission tomography/computed tomography in the evaluation of recurrence in 131I-negative papillary thyroid carcinoma.
    Saab G; Driedger AA; Pavlosky W; McDonald T; Wong CY; Yoo J; Urbain JL
    Thyroid; 2006 Mar; 16(3):267-72. PubMed ID: 16571089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
    Kim MH; O JH; Ko SH; Bae JS; Lim DJ; Kim SH; Baek KH; Lee JM; Kang MI; Cha BY; Lee KW
    Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan.
    Hung MC; Wu HS; Kao CH; Chen WK; Changlai SP
    Endocr Res; 2003 May; 29(2):169-75. PubMed ID: 12856803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
    Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
    Pachón-Garrudo VM; Cuenca-Cuenca JI; Ruiz-Franco-Baux J; Borrego-Dorado I; Tirado-Hospital JL; Navarro-González E; Vázquez-Albertino R
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):315-21. PubMed ID: 23084014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
    Shiga T; Tsukamoto E; Nakada K; Morita K; Kato T; Mabuchi M; Yoshinaga K; Katoh C; Kuge Y; Tamaki N
    J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value of 18F-FDG PET negativity and Tg suppressibility as markers of prognosis in patients with elevated Tg and 131I-negative differentiated thyroid carcinoma (TENIS syndrome).
    Ranade R; Kand P; Basu S
    Nucl Med Commun; 2015 Oct; 36(10):1014-20. PubMed ID: 26049373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma.
    Mirallié E; Guillan T; Bridji B; Resche I; Rousseau C; Ansquer C; Bodet-Milin C; Curtet C; Carnaille B; Murat A; Charbonnel B; Kraeber-Bodéré F
    Surgery; 2007 Dec; 142(6):952-8; discussion 952-8. PubMed ID: 18063081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
    Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC
    Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management.
    Schreinemakers JM; Vriens MR; Munoz-Perez N; Guerrero MA; Suh I; Rinkes IH; Gosnell J; Shen WT; Clark OH; Duh QY
    World J Surg Oncol; 2012 Sep; 10():192. PubMed ID: 22985118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography.
    Jadvar H; McDougall IR; Segall GM
    Nucl Med Commun; 1998 Jun; 19(6):547-54. PubMed ID: 10234658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic impact of (18)F-FDG PET/CT in recurrent differentiated thyroid carcinoma.
    Pomerri F; Cervino AR; Al Bunni F; Evangelista L; Muzzio PC
    Radiol Med; 2014 Feb; 119(2):97-102. PubMed ID: 24277507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of [(124)I]-PET/CT and [(18)F]-FDG-PET/CT for localizing recurrence in patients with differentiated thyroid carcinoma.
    Lee J; Nah KY; Kim RM; Oh YJ; An YS; Yoon JK; An GI; Choi TH; Cheon GJ; Soh EY; Chung WY
    J Korean Med Sci; 2012 Sep; 27(9):1019-26. PubMed ID: 22969247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
    Lee JW; Lee SM; Lee DH; Kim YJ
    J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Positron emission tomography-computed tomography with (18)F-fluorodeoxyglucose in patients with recurrent differentiated thyroid carcinoma and negative radioiodine scan. Diagnostic performance and relation with tyroglobulin levels].
    Mariscal Labrador E; García Burillo A; Castell-Conesa J; Obiols Alfonso G; Kisiel González N; Barios Profitós M; Aguadé-Bruix S; Mesa Manteca J
    Rev Esp Med Nucl Imagen Mol; 2013; 32(3):146-51. PubMed ID: 22726673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan].
    Ruiz Franco-Baux JV; Borrego Dorado I; Gómez Camarero P; Rodríguez Rodríguez JR; Vázquez Albertino RJ; Navarro González E; Astorga Jiménez R
    Rev Esp Med Nucl; 2005; 24(1):5-13. PubMed ID: 15701340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody.
    Kingpetch K; Pipatrattana R; Tepmongkol S; Sirisalipoch S; Chaiwatanarat T
    J Med Assoc Thai; 2011 Oct; 94(10):1238-44. PubMed ID: 22145510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.